Edwards Lifesciences Corporation
HealthcareNYSE:EW · New York Stock Exchange
-$1.03 today
Vol 2.19M · Avg 5.38M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $2.4B |
| Short-term Investments | $1.2B |
| Receivables | $973.0M |
| Inventory | $1.1B |
| Other Current | $464.2M |
| Total Current Assets | $6.2B |
| PP&E (Net) | $1.9B |
| Goodwill | $1.8B |
| Intangible Assets | $1.2B |
| Long-term Investments | $838.1M |
| Tax Assets | $1.1B |
| Other Non-current | $186.4M |
| Total Non-current Assets | $7.1B |
| Total Assets | $13.3B |
Analysis
Selected assets total $13.3B for Latest. The largest visible component is Cash & Equivalents at $2.4B, about 18.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.9B -3.5% | $3.0B +168.9% | $1.1B +47.2% | $769.0M -10.9% | $862.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $1.3B +38.4% | $930.7M +86.0% | $500.5M +12.1% | $446.3M -26.1% | $604.0M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $912.1M +25.4% | $727.4M -12.2% | $828.1M +18.5% | $699.1M +5.1% | $664.9M | $533.8M | $399.4M | -$1.7B |
| Inventory | $1.1B +3.6% | $1.1B +20.3% | $903.5M +3.2% | $875.5M +20.5% | $726.7M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $338.8M -9.5% | $374.4M -31.0% | $542.5M +176.9% | $195.9M -17.4% | $237.1M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $6.7B +7.2% | $6.3B +55.7% | $4.0B +30.4% | $3.1B -2.7% | $3.2B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $1.9B +7.3% | $1.8B +6.5% | $1.7B -2.9% | $1.7B +5.3% | $1.6B | $1.2B | $1.5B | $687.8M |
| Goodwill | $1.8B -0.5% | $1.8B +55.2% | $1.1B -1.6% | $1.2B -0.3% | $1.2B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $1.1B -4.1% | $1.2B +194.6% | $399.4M +40.0% | $285.2M -11.9% | $323.6M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $773.9M +151.3% | $307.9M -47.3% | $583.9M -52.9% | $1.2B -32.5% | $1.8B | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $1.1B +14.7% | $992.1M +32.4% | $749.4M +54.8% | $484.0M +96.2% | $246.7M | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $234.9M -67.9% | $732.4M -5.4% | $774.3M +158.9% | $299.1M +169.9% | $110.8M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $7.0B +2.8% | $6.8B +27.1% | $5.3B +2.5% | $5.2B -2.4% | $5.3B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $13.7B +4.9% | $13.1B +39.4% | $9.4B +12.9% | $8.3B -2.5% | $8.5B | $13.3B | $11.9B | $10.6B |
| Account Payables | $227.5M +15.2% | $197.4M +5.8% | $186.6M -7.6% | $201.9M -1.3% | $204.5M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $24.5M | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $374.7M +251.8% | $106.5M +10.7% | $96.2M -3.3% | $99.5M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $27.2M -49.3% | $53.7M | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $874.5M +97.5% | $442.7M -16.5% | $530.2M +73.8% | $305.0M -11.0% | $342.7M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $1.8B +20.5% | $1.5B +25.9% | $1.2B +16.9% | $1.0B -1.0% | $1.0B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $598.3M +0.1% | $597.7M +0.1% | $597.0M +0.1% | $596.3M +0.1% | $595.7M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $865.0M +6.7% | $810.6M +3.1% | $786.2M -1.4% | $797.6M -17.7% | $969.6M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $1.5B +3.9% | $1.5B +2.7% | $1.4B -1.0% | $1.5B -10.5% | $1.6B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $3.4B +12.3% | $3.0B +13.2% | $2.6B +6.4% | $2.5B -6.8% | $2.7B | $14.7B | $3.7B | $9.6B |
| Common Stock | $658.7M +0.6% | $654.8M +0.7% | $650.5M +0.6% | $646.3M +0.7% | $642.0M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $14.2B +8.2% | $13.2B +46.4% | $9.0B +18.5% | $7.6B +25.1% | $6.1B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$238.3M +2.5% | -$244.5M -0.7% | -$242.8M +4.7% | -$254.9M -61.6% | -$157.7M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 -100.0% | $64.5M -7.1% | $69.4M | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $10.3B +2.7% | $10.1B +49.8% | $6.7B +15.7% | $5.8B -0.5% | $5.8B | $9.1B | $7.7B | $3.3B |
| Total Debt | $705.4M +0.8% | $700.0M +2.2% | $685.1M -0.9% | $691.3M +0.1% | $690.3M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$2.2B +4.8% | -$2.3B -424.4% | -$447.2M -475.5% | -$77.7M +55.0% | -$172.5M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
argenx SE
NASDAQ:ARGX
$55.60B
Becton, Dickinson and Company
NYSE:BDX
$52.82B
Cardinal Health, Inc.
NYSE:CAH
$52.35B
Haleon plc
NYSE:HLN
$40.28B
Agilent Technologies, Inc.
NYSE:A
$36.52B
Alcon Inc.
NYSE:ALC
$32.50B
DexCom, Inc.
NASDAQ:DXCM
$28.77B
Veeva Systems Inc.
NYSE:VEEV
$25.79B
STERIS plc
NYSE:STE
$20.29B
Bruker Corporation
NASDAQ:BRKR
$8.16B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does EW have?
Edwards Lifesciences Corporation (EW) reported $2.94B in cash and equivalents in fiscal 2025.
How much debt does EW carry?
Edwards Lifesciences Corporation (EW) reported $705.40M of total debt, with net debt of -$2,233,100,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.